AUROBINDO PHARMA LTD. - 524804 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- B Adi ReddyDesignation :- Company Secretary and Compliance Officer
We refer to your email/letter dated October 11, 2021, seeking clarification on the captioned media report. Earlier during the year, the Company entered into a non-exclusive voluntary licensing agreement with MSD Pharmaceuticals for their investigational antiviral drug (Covid-19) molnupiravir. The Company has completed the trials for molnupiravir in mild Covid-19 patients as per protocol and the results have come out exceedingly well. The data for the same has been submitted to the Drug Controller General of India (DCGI) already. The Company has also conducted the trials for molnupiravir in 100 moderate Covid-19 patients. We have faced challenges in patient recruitment at this juncture and are evaluating further course of action. However, as the matter was not material in nature, the same did not warrant disclosure to the Stock Exchanges, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
We bring to your kind notice that the Company has received the letters from the following shareholders informing about the loss of share certificates and also requested for issue of duplicate share certificates: Sl. No. Folio No. Name of the Shareholder Certificate Nos. Distinctive Nos. No. of Equity Shares of Re.1/- each From To 1 APL025096 Niruth S V N 307449 292931733 292931792 60 2 APL021229 Nandlal R Sachdev Ashni N Suchdev 304009 292361396 292361425 30 3 APL029049 U G Prasanna 308412 292997408 292997437 30 4 APL027245 Bysani Krishna Murthy 307251 292921833 292921982 150 M/s KFin Technologies Private Limited, Registrar and Share Transfer Agents of the Company has recorded the stop transfer against the aforesaid shares and we are processing their requests for issue of duplicate share certificates.
The Exchange has sought clarification from Aurobindo Pharma Ltd with respect to news article appearing on https://www.thehindubusinessline.com October 08, 2021, titled "Aurobindo, MSN to halt Phase 3 trial in moderate Covid patients".The reply is awaited.
This is to certify that the details of securities dematerialized/rematerialized during the quarter ended September 30, 2021, as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, have been furnished to all the stock exchanges where the shares of the Company are listed. The letter confirming this from our RTA - M/s. KFin Technologies Private Limited dated October 5, 2021 is enclosed for your reference. Further, the certificates of securities which were dematerialized, are listed on the Stock Exchanges where earlier issued securities of the Company were listed.
Ref : BSE e-mail dated October 4, 2021. We refer to your email / letter dated October 4, 2021, seeking clarification on the captioned media report. We hereby confirm on the matter which involved recall of 2,820 bottles of Metoprolol tartrate tablets in the US market, and the recall was done at the pharmacy level. As the matter was not material in nature, the same did not warrant disclosure to the Stock Exchanges, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Exchange has sought clarification from Aurobindo Pharma Ltd with respect to news article appearing on https://www.business-standard.com October 3, 2021, titled "Drug makers Glenmark, Aurobindo Pharma recall products in US market".The reply is awaited.